[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

Objective.  —Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant disorder. The 3 recognized subtypes include MEN 2A, characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (pheo), and hyperparathyroidism (HPT); MEN 2B, by MTC, pheo, and characteristic stigmata; and familial MTC (FMTC), by the presence of MTC only. The purpose of this study was to establish the relationship between specific mutations and the presence of certain disease features in MEN 2 which could help in clinical decision making.

Design.  —Correlative survey study of 477 MEN 2 families.

Setting.  —Eighteen tertiary referral centers worldwide.

Patients.  —A total of 477 independent MEN 2 families.

Main Outcome Measures.  —Association between the position and type of germline mutation in the RET proto-oncogene and the presence or absence of MTC, pheo, HPT, and/or other features in a family.

Results.  —There is a statistically significant association between the presence of any mutation at a specific position (codon 634) and the presence of pheo and HPT. The presence of a specific mutation, CGC at codon 634, has yet to be associated with FMTC. Conversely, mutations at codons 768 and 804 are thus far seen only with FMTC, while codon 918 mutation is MEN 2B-specific. Rare families with both MEN 2 and Hirschsprung disease were found to have MEN 2-specific codon mutations. Patients with Hirschsprung disease presenting with such mutations should be monitored for the possible development of MEN 2 tumors.

Conclusions.  —This consortium analysis suggests that genotype-phenotype correlations do exist and, if made reliably absolute, could prove useful in the future in clinical management with respect to screening, surveillance, and prophylaxis, as well as provide insight into the genetic effects of particular mutations.

Schimke RN.  Genetic aspects of multiple endocrine neoplasia . Annu Rev Med . 1984;35:25-31.Article
Schimke RN, Hartmann WH, Prout TE, Rimoin DL.  Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas: a possible regulatory defect in the differentiation of chromaffin tissue . N Engl J Med . 1968;279:1-7.Article
Farndon JR, Leight GS, Dilley WG, et al.  Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity . Br J Surg . 1986;73:278-281.Article
Verdy M, Weber AM, Roy CC, Morin CL, Cadotte M, Brochu P.  Hirschsprung's disease in a family with multiple endocrine neoplasia . J Pediatr Gastroenterol Nutr . 1982;1:603-607.Article
Frilling A, Becker H, Roehr H-D.  Unusual features of multiple endocrine neoplasia . Henry Ford Hosp Med J . 1992;40:233-235.
Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA.  Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis . Ann Intern Med . 1989;111:802-806.Article
Mulligan LM, Kwok JBJ, Healey CS, et al.  Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A . Nature . 1993; 363:458-460.Article
Donis-Keller H, Dou S, Chi D, et al.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC . Hum Mol Genet . 1993;2:851-856.Article
Mulligan LM, Eng C, Healey CS, et al.  Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC . Nature Genet . 1994;6:70-74.Article
Eng C, Smith DP, Mulligan LM, et al.  A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC . Oncogene . 1995;10:509-513.
Bolino A, Schuffenecker I, Luo Y, et al.  RET mutations in exons 13 and 14 of FMTC patients . Oncogene . 1995;10:2415-2419.
Hofstra RMW, Landsvater RM, Ceccherini I, et al.  A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma . Nature . 1994;367:375-376.Article
Eng C, Smith DP, Mulligan LM, et al.  Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours . Hum Mol Genet . 1994;3:237-241.Article
Carlson KM, Dou S, Chi D, et al.  Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B . Proc Natl Acad Sci USA . 1994;91:1579-1583.Article
Reynolds LF, Eng C.  RET mutations in the MEN 2 syndromes and Hirschsprung disease . Curr Opin Pediatr . 1995;7:702-709.
Eng C, Mulligan LM. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2, related sporadic tumours and Hirschsprung disease. Hum Mutat. In press.
Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WKF, Heitz PU.  RET protooncogene point mutations in sporadic neuroendocrine tumors . J Clin Endocrinol Metab . 1996;81:2041-2046.Article
Pausova Z, Soliman E, Amizuka N, et al.  Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2 . Baillieres J Clin Endocrinol Metab . 1996;81:2711-2718.Article
Attié T, Pelet A, Edery P, et al.  Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease . Hum Mol Genet . 1995; 4:1381-1386.Article
Angrist M, Bolk S, Thiel B, et al.  Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease . Hum Mol Genet . 1995;4:821-830.Article
Okamoto E, Ueda T.  Embryogenesis of intramural ganglia of the gut and its relation to Hirschsprung disease . J Pediatr Surg . 1967;10:437-443.Article
Mulligan LM, Eng C, Attié T, et al.  Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene . Hum Mol Genet . 1994; 3:2163-2167.Article
Schuffenecker I, Billaud M, Calender A, et al.  RET proto-oncogene mutations in French MEN 2A and FMTC families . Hum Mol Genet . 1994;3:1939-1943.Article
Thakker RV, Ponder BAJ.  Multiple endocrine neoplasia . Clin Endocrinol Metab . 1988;28:1031-1068.
Mulligan LM, Marsh DJ, Robinson BG, et al.  Genotype-phenotype correlation in MEN 2: Report of the International RET Mutation Consortium . J Intern Med . 1995;238:343-346.Article
Lips CJM, Landsvater RM, Höppener JWM, et al.  Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A . N Engl J Med . 1994;331:828-835.Article
Marsh DJ, McDowall D, Hyland VJ, et al.  The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families . Clin Endocrinol . 1996;44:213-220.Article
Zedenius J, Larsson C, Bergholm U, et al.  Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinoma . J Clin Endocrinol Metab . 1995; 80:3088-3090.Article
Eng C, Mulligan LM, Smith DP, et al.  Low frequency of germline mutations in the RETprotooncogene in patients with apparently sporadic medullary thyroid carcinoma . Clin Endocrinol . 1995; 43:123-127.Article
Ponder BAJ, Finer N, Coffey R, et al.  Family screening in medullary thyroid carcinoma presenting without a family history . Q J Med . 1988;67:299-308.
Gardner E, Mulligan LM, Eng C, et al.  Haplotype analysis of MEN 2 mutations . Hum Mol Genet . 1994;3:1771-1774.Article
Hofstra R, Stelwagen T, Stulp R, et al.  RET mutations in MEN 2 associated diseases . Am J Hum Genet . 1994;55( (suppl 3) ):A60.
Borst MJ, van Camp JM, Peacock ML, Decker RA.  Mutation analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease . Surgery . 1995;117:386-389.Article
Noorani HZ, Khan HN, Gallie BL, Detsky AS.  Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma . Am J Hum Genet . 1996;59:301-307.
Komminoth P, Kunz EK, Matias-Guiu X, et al.  Analysis of RET proto-oncogene point mutations distinguished heritable from nonheritable medullary thyroid carcinomas . Cancer . 1995;76:479-489.Article